Puerarin attenuates hypoxia-resulted damages in neural stem cells by up-regulating microRNA-214
Source abstract
Abstract
Puerarin has been reported to be useful in protection against hypoxia-induced injury. In our current study, we attempted to explore the protective effects of puerarin against hypoxia-caused damages in neural stem cells (NSCs). Additionally, the relative molecular underpinning studies preliminarily proceeded. NSCs were pre-incubated with puerarin before the hypoxic stimulus. MicroRNA-214 (miR-214) inhibitor was transfected into NSCs. Subsequently, the viability of NSCs was assessed by CCK-8 assay. Flow cytometry was employed to detect apoptotic cells after staining. qRT-PCR was performed to quantify miR-214. Western blot was applied for analyzing the expression of apoptosis-relative proteins and regulators. We found that puerarin alleviated hypoxia-induced apoptosis and maintained cell viability. Hypoxia-evoked up-regulation of miR-214 was further enhanced by puerarin. By contrast, miR-214-deficient NSCs showed the reduction in cell viability and the facilitation in apoptosis progress after pre-treatment with puerarin and stimulation in a hypoxia circumstance. Additionally, puerarin restored the phosphorylation of relative regulators, which was originally blunted by hypoxia. However, puerarin did not evidently restore the phosphorylation for response to hypoxia in miR-214-silenced NSCs. In conclusion, puerarin might be applied as a novel agent to ameliorate hypoxia-evoked damages in NSCs. Molecularly, miR-214 might be implicated in the protective roles of puerarin.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: MicroRNA in disease regulation · Fatty Acid Research and Health · Circular RNAs in diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Neonatology, Linyi Women and Children’s Hospital
Department of Children's Healthcare, Linyi Women and Children's Hospital
References (35)
Show source-provided references
1. 10.1016/j.nbd.2015.08.02310.1016/j.nbd.2015.08.023 ↗
2. 10.1016/j.brainres.2015.10.02010.1016/j.brainres.2015.10.020 ↗
3. Jacobs SE, Berg M, Hunt R, et al. Cooling for newborns with hypoxic ischaemic encephalopathy. The Coch Database of Syst Rev. 2013;1:Cd003311.
4. 10.1016/j.ijdevneu.2015.03.01010.1016/j.ijdevneu.2015.03.010 ↗
5. 10.1016/j.biopha.2018.04.18410.1016/j.biopha.2018.04.184 ↗
6. 10.1016/j.biopha.2018.03.04010.1016/j.biopha.2018.03.040 ↗
7. 10.1055/s-2005-87126110.1055/s-2005-871261 ↗
8. 10.4238/gmr.1504750110.4238/gmr.15047501 ↗
9. 10.1016/j.theriogenology.2016.09.03310.1016/j.theriogenology.2016.09.033 ↗
10. Li Z, Xu W, Ren X, et al. Puerarin promotes DUSP1 expression by regulating miR133a3p in breast cancer. Mol Med Rep. 2019;19:205–212.
11. Shan Z, Cheng N, Huang R, et al. Puerarin promotes the proliferation and differentiation of MC3T3-E1 cells via microRNA-106b by targeting receptor activator of nuclear factor-kappaB ligand. Exper Therap Med. 2018;15:55–60.
12. 10.3892/mmr.2017.738610.3892/mmr.2017.7386 ↗
13. 10.1038/s41598-017-08450-810.1038/s41598-017-08450-8 ↗
14. 10.1038/onc.2015.27110.1038/onc.2015.271 ↗
15. 10.1016/j.canlet.2017.11.00710.1016/j.canlet.2017.11.007 ↗
16. 10.2147/COPD.S10462710.2147/COPD.S104627 ↗
17. Wan DY, Zhang Z, Yang HH. Cardioprotective effect of miR-214 in myocardial ischemic postconditioning by down-regulation of hypoxia inducible factor 1, alpha subunit inhibitor. Cell Mol Biol. 2015;61:1–6.
18. 10.1371/journal.pone.005527610.1371/journal.pone.0055276 ↗
19. Liu PY, Tian Y, Xu SY. Mediated protective effect of electroacupuncture pretreatment by miR-214 on myocardial ischemia/reperfusion injury. J Ger Cardiol. 2014;11:303–310.
20. 10.1016/j.cmet.2013.08.00910.1016/j.cmet.2013.08.009 ↗
21. 10.1159/00004614910.1159/000046149 ↗
22. 10.1159/00044782210.1159/000447822 ↗
23. Wu H, Wang H, Zhang B, et al. Puerarin decreases hypoxia inducible factor-1 alpha in the hippocampus of vascular dementia rats. Neur Regen Res. 2012;7:421–425.
24. 10.1016/j.intimp.2016.09.01010.1016/j.intimp.2016.09.010 ↗
25. 10.1074/jbc.M00780720010.1074/jbc.M007807200 ↗
26. 10.1523/JNEUROSCI.18-10-03659.199810.1523/JNEUROSCI.18-10-03659.1998 ↗
27. 10.1023/A:102034773274110.1023/A:1020347732741 ↗
28. 10.18632/oncotarget.2229010.18632/oncotarget.22290 ↗
29. 10.1016/j.neuropharm.2013.12.00410.1016/j.neuropharm.2013.12.004 ↗
30. 10.12659/MSM.89605810.12659/MSM.896058 ↗
31. 10.1371/journal.pone.009985510.1371/journal.pone.0099855 ↗
32. 10.1172/JCI5932710.1172/JCI59327 ↗
33. 10.1038/jcbfm.2009.10210.1038/jcbfm.2009.102 ↗
34. 10.1016/j.toxlet.2012.05.00610.1016/j.toxlet.2012.05.006 ↗
35. 10.18632/oncotarget.1349410.18632/oncotarget.13494 ↗